论文部分内容阅读
目的 :探讨米非司酮治疗子宫肌瘤的临床效果。方法 :将确诊为子宫肌瘤的患者40例采用口服米非司酮连服 3～ 6个月 ,1次 /d ,2 5mg/次 ,于治疗前后均用三维B超监测子宫肌瘤体积、检测血常规、肝功、肾功、心电图及FSH、LH、PRL、E2 、P等指标。结果 :患者治疗期间均发生闭经、症状消失、子宫肌瘤明显缩小 ( 1个月缩小 2 1 % ,2个月缩小为 38% ,3个月后缩小为 5 4% ,P <0 0 5 ) ,血色素上升至正常 ,FSH明显下降 ,血中P、E2 水平明显降低 ,其它监测指标均无明显改变。结论 :米非司酮治疗子宫效果肯定 ,副作用小、安全 ,是一种可行的治疗方法。
Objective: To investigate the clinical efficacy of mifepristone in the treatment of uterine fibroids. Methods: Forty patients diagnosed as uterine fibroids were treated with oral mifepristone for 3 to 6 months, once / d and 25 mg once daily. The volume of uterine fibroids was monitored by three-dimensional B-ultrasound before and after treatment. Blood tests, liver function, renal function, ECG and FSH, LH, PRL, E2, P and other indicators. Results: Amenorrhoea occurred during treatment, symptoms disappeared and uterine fibroids were significantly reduced (21% in 1 month, 38% in 2 months and 54% in 3 months, P <0 05) , Hemoglobin rose to normal, FSH decreased significantly, blood P, E2 levels decreased significantly, the other monitoring indicators had no significant change. Conclusion: Mifepristone treatment of the uterus affirmative, side effects, safety, is a viable treatment.